Previous 10 | Next 10 |
Like meme stocks will do from time to time, Ocugen (NASDAQ: OCGN) on Wednesday saw a notable price drop a day after a surge. The company was hit by quite a severe price target cut from an analyst, a move that ruined the party after Tuesday's post-earnings run-up. Before market o...
There's nothing like a good quarter to juice a company's stock. That was the case on Tuesday with ambitious biotech Ocugen (NASDAQ: OCGN) , whose share price leaped 7% higher after the company unveiled its third-quarter results. Ocugen, which surged to prominence during the coro...
Ocugen ( NASDAQ: OCGN ) is trading 9.2% higher after the company posted Q3 GAAP EPS of -$0.10 in-line with estimates. The company said it completed enrollment of U.S. Phase 2/3 Covaxin trial and expects top line data in early 2023. The Company has cash of ...
Ocugen, Inc. (OCGN) Q3 2022 Earnings Conference Call November 08, 2022 08:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Offic...
Ocugen press release ( NASDAQ: OCGN ): Q3 GAAP EPS of -$0.10 in-line. The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021 Initiated dosing in t...
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trial Expanded product pipeline with OCU500—Ocugen’s mucosal COVID-19 vaccine and OCU410ST for Stargardt diseas...
Ocugen ( NASDAQ: OCGN ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market opens. The consensus EPS Estimate is -$0.10 (-100.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward r...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Financial markets have been in turmoil for the better part of the past six months. The stock market has plunged to new lows as the Federal Reserve tightens the screws with rampant interest rate hikes. That said, this market...
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host ...
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, ...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...